Alisertib in HR+, HER2- Metastatic Breast Cancer: Phase II Trial Launch
Puma Biotechnology initiated its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285). This trial investigates alisertib combined with...
Real-World Data Addresses Cancer Care Gaps in Older Adults
COTA, Inc., a real-world data (RWD) and analytics company specializing in oncology, and Memorial Sloan Kettering Cancer Center (MSK)...
Glox Therapeutics Awarded £1M Grant to Develop Precision Antibiotics
Glox Therapeutics, a company developing precision antibiotic therapies using naturally occurring bacteriocins, has received £1 million in grant funding...
Pfizer Appoints New Chief Scientific Officer
Pfizer has appointed Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development,...
Bill Nye, the Science Guy, explains ataxia to Congressional briefing
The National Ataxia Foundation (NAF) recently collaborated with members of Congress to conduct an informational meeting about Spinocerebellar Ataxia...
Immunis Achieves Breakthrough in Muscle Atrophy Trial
Immunis, Inc., a clinical-stage biotechnology company, has successfully completed a Phase 1/2a clinical trial of IMM01-STEM, a novel multi-active...
Asimov, Revopsis Sign Licensing Deal for Multispecific-Expressing Cell Line
Asimov, a synthetic biology company focused on therapeutic design and manufacturing, has entered into a licensing agreement with RevOpsis...
Steritas & Argenx Announce Collaboration to Advance Steroid-Sparing Therapeutics
Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company...
AgelessRx Enters Sleep Health Market
AgelessRx, a leading telehealth platform specializing in longevity, has expanded its services to include sleep health. Recognizing the crucial...
Otsuka Provides Sibeprenlimab Update for IgA Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical Co., Ltd. plan to submit a Biologics License Application...